Longeveron Inc. (LGVN) vs NeuroSense Therapeutics Ltd. (NRSN)

A side-by-side comparison of Longeveron Inc. and NeuroSense Therapeutics Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

LGVN

Longeveron Inc.

$7M

$2.39HealthcareDelayed quote: Oct 6, 2026, 12:50 PM EDT

NRSN

NeuroSense Therapeutics Ltd.

$7M

$3.91HealthcareDelayed quote: Oct 6, 2026, 12:48 PM EDT

Total return — LGVN vs NRSN

growth of $100 · dividends reinvested · last 5y

LGVN -99.9% (-73.5%/yr)NRSN -95.0% (-45.1%/yr)NRSN compounded faster over this window

Log scale — wide-divergence pair

LGVN NRSN

LGVN vs NRSN: by the numbers

•LGVN is the larger company ($7M vs $7M market cap).
•Both run net losses; NRSN's is the smaller (0.00% vs -1977.59% net margin).

Metrics side by side

Valuation

Metric	LGVN	NRSN
P/S ratio	6.13	N/A
P/B ratio	0.70	N/A

Profitability

Metric	LGVN	NRSN
Gross margin	69.76%	0.00%
Operating margin	-1942.20%	0.00%
Net margin	-1977.59%	0.00%
ROE	-225.67%	N/A
ROIC	-211.58%	N/A

Growth (annualized)

Metric	LGVN	NRSN
Revenue CAGR (5Y)	-21.21%	N/A
Total return CAGR (5Y)	-62.60%	N/A

Go deeper

Full LGVN analysis Full NRSN analysis Interactive comparison tool

Dig into the metrics

Longeveron ROE NeuroSense Therapeutics ROE Longeveron operating margin NeuroSense Therapeutics operating margin Longeveron revenue growth NeuroSense Therapeutics revenue growth Longeveron free cash flow NeuroSense Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.